grepcent public filings, reorganized for comparison

Prestige Consumer Healthcare Inc. (PBH)

CIK: 0001295947. SIC: 2834 Pharmaceutical Preparations. Latest 10-K as of: 2026-05-14.

SIC breadcrumb: Manufacturing > Chemicals And Allied Products > SIC 2834 Pharmaceutical Preparations

SEC company page: https://www.sec.gov/edgar/browse/?CIK=1295947. Latest filing source: 0001295947-26-000016.

Informational only. Descriptive public-record data — not a rating, forecast, or investment advice. See Disclaimer.

At a glance

FY2026 · period end 2026-03-31 · filed 2026-05-14 · accession 0001295947-26-000016 · source: SEC companyfacts

Revenue
1,088,705,000 USD verified
Net income
190,301,000 USD verified
Assets
3,494,313,000 USD verified
Free cash flow
246,449,000 USD computed
Net margin
17.48% computed
Operating margin
28.42% computed
Revenue YoY
-4.31% computed
ROE
10.08% computed

Computed values are grepcent-computed from the verified facts above and may differ from ratios the company itself reports. Free cash flow = operating cash flow − capital expenditures. Net margin = net income ÷ revenue. Operating margin = operating income ÷ revenue. Revenue YoY = FY2026 revenue ÷ FY2025 revenue − 1 (consecutive fiscal years only). ROE = net income ÷ period-end stockholders' equity.

No market price, no rating, no forecast on this site. Not investment advice.

Peer & cluster context

Peer percentile fingerprint

PBH ratios vs SIC peers. Source: grepcent computed from latest SEC companyfacts ratios; peer set SIC industry 2834; per-ratio N printed.PBH ratios vs SIC peers. Source: grepcent computed from latest SEC companyfacts ratios; peer set SIC industry 2834; per-ratio N printed.RatioPBHPeer medianPercentileNNet margin17.5%1.0%75107Operating margin28.4%-1.3%89100Revenue growth-4.3%14.7%19127FCF margin22.6%-14.0%82127ROE10.1%-30.7%77171ROA5.4%-21.8%80187Liabilities / equity0.850.3865173Current ratio3.574.8937188

Percentile = share of the N covered peers reporting that ratio whose value is lower (ties counted half); computed among grepcent-covered companies in SIC industry 2834 Pharmaceutical Preparations, not the whole market. A higher percentile means a higher value of the ratio, not a better company. Ratios with fewer than 8 reporting peers are omitted. Latest reported values per company; fiscal periods may differ. Descriptive arithmetic - not a score, rating, or ranking.

Selected Fundamentals

MetricValueUnitFYFiled
Revenue1,088,705,000USD20262026-05-14
Net income190,301,000USD20262026-05-14
Assets3,494,313,000USD20262026-05-14

Financials

Annual standardized facts from SEC companyfacts as of latest extracted filing date 2026-05-14. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0001295947.json. Derived margins, ratios, and free cash flow are computed from the extracted annual SEC facts.

Download these verified figures (annual + quarterly, with per-value filing provenance): JSON · CSV

Flow metrics use full-year FY periods from 10-K/10-K/A filings; balance-sheet metrics use FY-end instants. Free cash flow = operating cash flow - capital expenditures. Missing metrics are omitted rather than fabricated.

Metric2017201820192020202120222023202420252026
Revenue882,060,0001,041,179,000975,777,000963,010,000943,365,0001,086,812,0001,127,725,0001,125,357,0001,137,762,0001,088,705,000
Net income69,395,000339,570,000-35,800,000142,281,000164,682,000205,381,000-82,306,000209,339,000214,605,000190,301,000
Operating income205,643,000215,474,00067,503,000291,155,000297,402,000329,919,000-22,415,000342,429,000336,775,000309,409,000
Gross profit500,286,000576,505,000555,576,000552,223,000547,472,000620,646,000625,294,000624,448,000634,463,000595,578,000
Diluted EPS1.306.34-0.692.783.254.04-1.654.174.293.91
Operating cash flow148,672,000210,110,000189,284,000217,124,000235,607,000259,922,000229,716,000248,926,000251,515,000257,627,000
Capital expenditures2,977,00012,532,00010,480,00014,560,00022,243,0009,642,0007,784,0009,550,0008,224,00011,178,000
Share buybacks0.000.0049,978,00056,721,00011,867,0000.0050,000,00025,000,00051,509,000156,283,000
Assets3,911,348,0003,760,612,0003,441,036,0003,513,905,0003,429,273,0003,670,681,0003,353,729,0003,318,417,0003,402,218,0003,494,313,000
Liabilities3,088,799,0002,582,002,0002,345,205,0002,342,934,0002,070,975,0002,093,070,0001,906,645,0001,663,333,0001,567,321,0001,606,797,000
Stockholders' equity822,549,0001,178,610,0001,095,831,0001,170,971,0001,358,298,0001,577,611,0001,447,084,0001,655,084,0001,834,897,0001,887,516,000
Cash and cash equivalents41,855,00032,548,00027,530,00094,760,00032,302,00027,185,00058,489,00046,469,00097,884,00063,868,000
Free cash flow145,695,000197,578,000178,804,000202,564,000213,364,000250,280,000221,932,000239,376,000243,291,000246,449,000

Ratios

ROE and ROA use period-end equity/assets. Liabilities / equity uses total liabilities divided by stockholders' equity. Current ratio uses current assets divided by current liabilities when both are reported.

Metric2017201820192020202120222023202420252026
Net margin7.87%32.61%-3.67%14.77%17.46%18.90%-7.30%18.60%18.86%17.48%
Operating margin23.31%20.70%6.92%30.23%31.53%30.36%-1.99%30.43%29.60%28.42%
Return on equity8.44%28.81%-3.27%12.15%12.12%13.02%-5.69%12.65%11.70%10.08%
Return on assets1.77%9.03%-1.04%4.05%4.80%5.60%-2.45%6.31%6.31%5.45%
Liabilities / equity3.762.192.142.001.521.331.321.000.850.85
Current ratio2.062.462.372.442.212.042.443.204.203.57

Industry Peer Context

Each number-line places PBH against the min, median, and max of latest reported values among companies in the same SIC industry when at least three peers report that ratio.

Net margin peer context

PBH Net margin versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 2834; peer count 107.PBH Net margin versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 2834; peer count 107.107 SIC peersMin -146.0%Median 1.0%Max 124.7%PBH 17.5%

Operating margin peer context

PBH Operating margin versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 2834; peer count 100.PBH Operating margin versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 2834; peer count 100.100 SIC peersMin -149.3%Median -1.3%Max 65.6%PBH 28.4%

ROE peer context

PBH ROE versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 2834; peer count 171.PBH ROE versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 2834; peer count 171.171 SIC peersMin -441.6%Median -30.7%Max 128.7%PBH 10.1%

ROA peer context

PBH ROA versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 2834; peer count 187.PBH ROA versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 2834; peer count 187.187 SIC peersMin -163.7%Median -21.8%Max 71.5%PBH 5.4%

Financial Bridges

Waterfall figures reconcile reported SEC companyfacts components. Missing bridges are omitted when required components are not present for the same fiscal year.

Income statement bridge from reported figures

PBH FY2026 income statement bridge from reported figures.PBH FY2026 income statement bridge from reported figures.PBH income bridgeFY2026: revenue to net incomeSource: SEC companyfacts FY2026.Income statement bridgeReported amount$0.0B$1.0B$2.0B$1.1BRevenue-$493.1MCost$595.6MGross-$286.2MOpEx$309.4MOperating-$119.1MOther/tax$190.3MNet income

Figure provenance: SEC companyfacts FY 2026. Revenue: accession 0001295947-26-000016; concept RevenueFromContractWithCustomerExcludingAssessedTax; source concepts us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | Gross profit: accession 0001295947-26-000016; concept GrossProfit; source concepts us-gaap:GrossProfit | Operating income: accession 0001295947-26-000016; concept OperatingIncomeLoss; source concepts us-gaap:OperatingIncomeLoss | Net income: accession 0001295947-26-000016; concept NetIncomeLoss; source concepts us-gaap:NetIncomeLoss

Free cash flow = operating cash flow - capital expenditures

PBH FY2026 free cash flow bridge from reported figures.PBH FY2026 free cash flow bridge from reported figures.PBH free cash flow bridgeFY2026: operating cash flow less capital expendituresSource: SEC companyfacts FY2026.Free cash flow bridgeReported amount$0.0B$250.0M$500.0M$257.6MOperating cash flow-$11.2MCapex$246.4MFree cash flow

Figure provenance: SEC companyfacts FY 2026. Operating cash flow: accession 0001295947-26-000016; concept NetCashProvidedByUsedInOperatingActivities; source concepts us-gaap:NetCashProvidedByUsedInOperatingActivities | Capital expenditures: accession 0001295947-26-000016; concept PaymentsToAcquirePropertyPlantAndEquipment; source concepts us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | Free cash flow: accession 0001295947-26-000016; concept NetCashProvidedByUsedInOperatingActivities - PaymentsToAcquirePropertyPlantAndEquipment; source concepts us-gaap:NetCashProvidedByUsedInOperatingActivities; us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

Financial Charts

PBH revenue, last 5 periods. Source: SEC companyfacts FY2026.PBH revenue, last 5 periods. Source: SEC companyfacts FY2026.PBH RevenueLatest point: FY2026 = $1.1BSource: SEC companyfacts FY2026.Fiscal yearReported revenue$0.0B$1.0B$2.0BFY2022FY2023FY2024FY2025FY2026

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-03-31; accession 0001295947-26-000016; filed 2026-05-14. Concept: RevenueFromContractWithCustomerExcludingAssessedTax. Source concepts: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

PBH net income, last 5 periods. Source: SEC companyfacts FY2026.PBH net income, last 5 periods. Source: SEC companyfacts FY2026.PBH Net incomeLatest point: FY2026 = $190.3MSource: SEC companyfacts FY2026.Fiscal yearNet income-$250.0M$0.0B$500.0MFY2022FY2023FY2024FY2025FY2026

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-03-31; accession 0001295947-26-000016; filed 2026-05-14. Concept: NetIncomeLoss. Source concepts: us-gaap:NetIncomeLoss.

PBH operating income, last 5 periods. Source: SEC companyfacts FY2026.PBH operating income, last 5 periods. Source: SEC companyfacts FY2026.PBH Operating incomeLatest point: FY2026 = $309.4MSource: SEC companyfacts FY2026.Fiscal yearOperating income-$250.0M$0.0B$500.0MFY2022FY2023FY2024FY2025FY2026

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-03-31; accession 0001295947-26-000016; filed 2026-05-14. Concept: OperatingIncomeLoss. Source concepts: us-gaap:OperatingIncomeLoss.

PBH gross profit, last 5 periods. Source: SEC companyfacts FY2026.PBH gross profit, last 5 periods. Source: SEC companyfacts FY2026.PBH Gross profitLatest point: FY2026 = $595.6MSource: SEC companyfacts FY2026.Fiscal yearGross profit$0.0B$375.0M$750.0MFY2022FY2023FY2024FY2025FY2026

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-03-31; accession 0001295947-26-000016; filed 2026-05-14. Concept: GrossProfit. Source concepts: us-gaap:GrossProfit.

PBH diluted eps, last 5 periods. Source: SEC companyfacts FY2026.PBH diluted eps, last 5 periods. Source: SEC companyfacts FY2026.PBH Diluted EPSLatest point: FY2026 = $3.91/shareSource: SEC companyfacts FY2026.Fiscal yearDiluted EPS (USD/share)-$2.00/share$0.00/share$6.00/shareFY2022FY2023FY2024FY2025FY2026

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-03-31; accession 0001295947-26-000016; filed 2026-05-14. Concept: EarningsPerShareDiluted. Source concepts: us-gaap:EarningsPerShareDiluted.

PBH operating cash flow, last 5 periods. Source: SEC companyfacts FY2026.PBH operating cash flow, last 5 periods. Source: SEC companyfacts FY2026.PBH Operating cash flowLatest point: FY2026 = $257.6MSource: SEC companyfacts FY2026.Fiscal yearOperating cash flow$0.0B$250.0M$500.0MFY2022FY2023FY2024FY2025FY2026

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-03-31; accession 0001295947-26-000016; filed 2026-05-14. Concept: NetCashProvidedByUsedInOperatingActivities. Source concepts: us-gaap:NetCashProvidedByUsedInOperatingActivities.

PBH capital expenditures, last 5 periods. Source: SEC companyfacts FY2026.PBH capital expenditures, last 5 periods. Source: SEC companyfacts FY2026.PBH Capital expendituresLatest point: FY2026 = $11.2MSource: SEC companyfacts FY2026.Fiscal yearCapital expenditures$0.0B$125.0M$250.0MFY2022FY2023FY2024FY2025FY2026

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-03-31; accession 0001295947-26-000016; filed 2026-05-14. Concept: PaymentsToAcquirePropertyPlantAndEquipment. Source concepts: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

PBH share buybacks, last 5 periods. Source: SEC companyfacts FY2026.PBH share buybacks, last 5 periods. Source: SEC companyfacts FY2026.PBH Share buybacksLatest point: FY2026 = $156.3MSource: SEC companyfacts FY2026.Fiscal yearShare buybacks$0.0B$125.0M$250.0MFY2022FY2023FY2024FY2025FY2026

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-03-31; accession 0001295947-26-000016; filed 2026-05-14. Concept: PaymentsForRepurchaseOfCommonStock. Source concepts: us-gaap:PaymentsForRepurchaseOfCommonStock.

PBH assets, last 5 periods. Source: SEC companyfacts FY2026.PBH assets, last 5 periods. Source: SEC companyfacts FY2026.PBH AssetsLatest point: FY2026 = $3.5BSource: SEC companyfacts FY2026.Fiscal yearAssets$0.0B$2.0B$4.0BFY2022FY2023FY2024FY2025FY2026

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-03-31; accession 0001295947-26-000016; filed 2026-05-14. Concept: Assets. Source concepts: us-gaap:Assets.

PBH liabilities, last 5 periods. Source: SEC companyfacts FY2026.PBH liabilities, last 5 periods. Source: SEC companyfacts FY2026.PBH LiabilitiesLatest point: FY2026 = $1.6BSource: SEC companyfacts FY2026.Fiscal yearLiabilities$0.0B$2.0B$4.0BFY2022FY2023FY2024FY2025FY2026

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-03-31; accession 0001295947-26-000016; filed 2026-05-14. Concept: Liabilities. Source concepts: us-gaap:Liabilities.

PBH stockholders' equity, last 5 periods. Source: SEC companyfacts FY2026.PBH stockholders' equity, last 5 periods. Source: SEC companyfacts FY2026.PBH Stockholders' equityLatest point: FY2026 = $1.9BSource: SEC companyfacts FY2026.Fiscal yearStockholders' equity$0.0B$1.0B$2.0BFY2022FY2023FY2024FY2025FY2026

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-03-31; accession 0001295947-26-000016; filed 2026-05-14. Concept: StockholdersEquity. Source concepts: us-gaap:StockholdersEquity.

PBH cash and cash equivalents, last 5 periods. Source: SEC companyfacts FY2026.PBH cash and cash equivalents, last 5 periods. Source: SEC companyfacts FY2026.PBH Cash and cash equivalentsLatest point: FY2026 = $63.9MSource: SEC companyfacts FY2026.Fiscal yearCash and cash equivalents$0.0B$125.0M$250.0MFY2022FY2023FY2024FY2025FY2026

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-03-31; accession 0001295947-26-000016; filed 2026-05-14. Concept: CashAndCashEquivalentsAtCarryingValue. Source concepts: us-gaap:CashAndCashEquivalentsAtCarryingValue.

PBH free cash flow, last 5 periods. Source: SEC companyfacts FY2026.PBH free cash flow, last 5 periods. Source: SEC companyfacts FY2026.PBH Free cash flowLatest point: FY2026 = $246.4MSource: SEC companyfacts FY2026.Fiscal yearFree cash flow$0.0B$250.0M$500.0MFY2022FY2023FY2024FY2025FY2026

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-03-31; accession 0001295947-26-000016; filed 2026-05-14. Concept: NetCashProvidedByUsedInOperatingActivities - PaymentsToAcquirePropertyPlantAndEquipment. Source concepts: us-gaap:NetCashProvidedByUsedInOperatingActivities; us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

As-reported value updates

No tracked differences above grepcent's stated thresholds and capped precision rule were found between the earliest XBRL-filed value and the value currently on file for the standardized annual metrics grepcent tracks.

Quarterly

Quarterly standardized facts from SEC companyfacts as of latest extracted filing date 2026-08-06. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0001295947.json.

Flow metrics use discrete quarter-length periods from 10-Q/10-Q/A filings. Q4 revenue and net income are derived only when annual FY and nine-month YTD facts exist for the same fiscal year; derived Q4 values are labeled. EPS Q4 is not derived.

QuarterEnd DateRevenueNet IncomeDiluted EPSMethod
2023-Q22022-09-301.02reported discrete quarter
2023-Q32022-12-311.04reported discrete quarter
2024-Q12023-06-301.06reported discrete quarter
2024-Q22023-09-30286,316,00053,559,0001.07reported discrete quarter
2024-Q32023-12-31282,741,00053,046,0001.06reported discrete quarter
2024-Q42024-03-31276,991,00049,458,000derived Q4 = FY annual - nine-month YTD
2025-Q12024-06-30267,142,00049,068,0000.98reported discrete quarter
2025-Q22024-09-30283,785,00054,377,0001.09reported discrete quarter
2025-Q32024-12-31290,317,00061,032,0001.22reported discrete quarter
2025-Q42025-03-31296,518,00050,128,000derived Q4 = FY annual - nine-month YTD
2026-Q12025-06-30249,530,00047,466,0000.95reported discrete quarter
2026-Q22025-09-30274,114,00042,211,0000.86reported discrete quarter
2026-Q32025-12-31283,444,00046,696,0000.97reported discrete quarter
2026-Q42026-03-31281,617,00053,928,000derived Q4 = FY annual - nine-month YTD
2027-Q12026-06-30265,710,00029,177,0000.61reported discrete quarter

Quarterly Charts

PBH quarterly revenue, last 12 periods. Source: SEC companyfacts 2027-Q1.PBH quarterly revenue, last 12 periods. Source: SEC companyfacts 2027-Q1.PBH Quarterly RevenueLatest point: 2027-Q1 = $265.7MSource: SEC companyfacts 2027-Q1.Fiscal quarterQuarterly Revenue$0.0B$250.0M$500.0M2024-Q22024-Q32024-Q42025-Q12025-Q22025-Q32025-Q42026-Q12026-Q22026-Q32026-Q42027-Q1

Figure provenance: SEC companyfacts. Latest point: FY 2027 ended 2026-06-30; accession 0001295947-26-000042; filed 2026-08-06. Concept: RevenueFromContractWithCustomerExcludingAssessedTax. Source concepts: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

PBH quarterly net income, last 12 periods. Source: SEC companyfacts 2027-Q1.PBH quarterly net income, last 12 periods. Source: SEC companyfacts 2027-Q1.PBH Quarterly Net incomeLatest point: 2027-Q1 = $29.2MSource: SEC companyfacts 2027-Q1.Fiscal quarterQuarterly Net income$0.0B$125.0M$250.0M2024-Q22024-Q32024-Q42025-Q12025-Q22025-Q32025-Q42026-Q12026-Q22026-Q32026-Q42027-Q1

Figure provenance: SEC companyfacts. Latest point: FY 2027 ended 2026-06-30; accession 0001295947-26-000042; filed 2026-08-06. Concept: NetIncomeLoss. Source concepts: us-gaap:NetIncomeLoss.

PBH quarterly diluted eps, last 12 periods. Source: SEC companyfacts 2027-Q1.PBH quarterly diluted eps, last 12 periods. Source: SEC companyfacts 2027-Q1.PBH Quarterly Diluted EPSLatest point: 2027-Q1 = $0.61/shareSource: SEC companyfacts 2027-Q1.Fiscal quarterQuarterly Diluted EPS (USD/share)$0.00/share$0.75/share$1.50/share2023-Q22023-Q32024-Q12024-Q22024-Q32025-Q12025-Q22025-Q32026-Q12026-Q22026-Q32027-Q1

Figure provenance: SEC companyfacts. Latest point: FY 2027 ended 2026-06-30; accession 0001295947-26-000042; filed 2026-08-06. Concept: EarningsPerShareDiluted. Source concepts: us-gaap:EarningsPerShareDiluted.

Business

Read PBH's verbatim Item 1 Business section from its latest 10-K: Business.

Risk Factors

Read PBH's verbatim Item 1A Risk Factors from its latest 10-K: Risk Factors.

Latest quarter (10-Q)

Latest 10-Q source: 0001295947-26-000042.

Extracted structurally from real Item 2 body heading to real Item 3/4 boundary. Confidence: high. Filing date: 2026-08-06. Report date: 2026-06-30.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion of our financial condition and results of operations should be read together with the Condensed Consolidated Financial Statements and the related notes included in this Quarterly Report on Form 10-Q, as well as our Annual Report on Form 10-K for the fiscal year ended March 31, 2026.  This discussion and analysis may contain forward-looking statements that involve certain risks, assumptions and uncertainties.  Future results could differ materially from the discussion that follows for many reasons, including the factors described in Part I, Item 1A. “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended March 31, 2026 and in future reports filed with the U.S. Securities and Exchange Commission ("SEC").

See also “Cautionary Statement Regarding Forward-Looking Statements” on page 29 of this Quarterly Report on Form 10-Q.

Unless otherwise indicated by the context, all references in this Quarterly Report on Form 10-Q to “we,” “us,” “our,” the “Company” or “Prestige” refer to Prestige Consumer Healthcare Inc. and our subsidiaries. Similarly, references to a year (e.g., 2027) refer to our fiscal year ended March 31 of that year.

General

We are engaged in the development, manufacturing, marketing, sales and distribution of well-recognized, brand name, over-the-counter ("OTC") health and personal care products to mass merchandisers, drug, food, dollar, convenience and club stores and e-commerce channels in North America (the United States and Canada) and in Australia and certain other international markets.  We use the strength of our brands, our established retail distribution network, a low-cost operating model and our experienced management team to our competitive advantage.

We have grown our brand portfolio both organically and through acquisitions. We develop our existing brands by investing in new product lines, brand extensions and strong advertising support. Acquisitions of consumer health and personal care brands have also been an important part of our growth strategy. We have acquired well-recognized brands from consumer products and pharmaceutical companies and private equity firms. While many of these brands have long histories of brand development and investment, we believe that, at the time we acquired them, most were considered “non-core” by their previous owners. As a result, these acquired brands did not benefit from adequate management focus and marketing support during the period prior to their acquisition, which created opportunities for us to reinvigorate these brands and improve their performance post-acquisition. After adding a core brand to our portfolio, we seek to increase its sales, market share and distribution in both existing and new channels through our established retail distribution network.  We pursue this growth through increased spending on advertising and marketing support, new sales and marketing strategies, improved packaging and formulations, and innovative development of brand extensions.

Acquisitions

Acquisition of the OTC Wellness Business

On June 12, 2026, we completed the acquisition of Breathe Right and certain other brands (the "OTC Wellness Business"), from Foundation Consumer Brands, LLC and certain of its affiliates for a purchase price of $1,045.0 million in cash (the "Breathe Right Acquisition"). In connection with this acquisition, we entered into a Term Loan Credit Agreement on June 12, 2026 (the "Term Loan Credit Agreement") providing for term loans in the amount of $1,045.0 million, the proceeds of which were used to, along with cash on hand, finance the Breathe Right Acquisition and fees and expenses incurred in connection with the closing of the Term Loan Credit Agreement and the Breathe Right Acquisition. As a result of this acquisition, we acquired certain assets primarily related to a portfolio of over-the-counter consumer health products.

The results of the OTC Wellness Business have been included in our consolidated financial statements from the acquisition date. Unaudited pro forma financial information giving effect to the acquisition as if it had occurred at the beginning of fiscal 2026 is included in Note 2., Acquisitions.

Acquisition of Pillar5

On December 18, 2025, we completed the acquisition of Pillar5 Pharma, Inc. ("Pillar5"), which was funded through a combination of cash on hand and our existing asset-based revolving credit facility.

Based in Ontario, Canada, Pillar5 is a leading sterile ophthalmic manufacturer and one of our current Clear Eyes suppliers.

The pro-forma effect of this acquisition on revenues and earnings was not material.

22

The details of the OTC Wellness Business and Pillar5 acquisitions are included in the notes to the unaudited Condensed Consolidated Financial Statements in Part I, Item I, Note 2., Acquisitions, of this Quarterly Report on Form 10-Q.

Economic Environment

There has been economic uncertainty in the United States and globally due to several factors, including evolving fiscal policy, global supply chain constraints, changes in interest rates, a high inflationary environment, geopolitical events and evolving U.S. and international trade restrictions and tariffs. We expect economic conditions will continue to be highly volatile and uncertain, put pressure on prices and supply, and could affect demand for our products. We have continued to see changes in the purchasing patterns of our consumers, including a shift in many markets to purchasing our products online, and have and may continue to see changes in retailer purchasing patterns due to these consumer patterns and the uncertain economic environment.

The volatile environment has impacted the supply of labor and raw materials and exacerbated rising input costs. We have and may continue to experience shortages, delays and backorders for certain ingredients and products, difficulty scheduling shipping for our products, as well as price increases from many of our suppliers for both shipping and product costs. If conditions cause further disruption in the global supply chain, the availability of labor and materials or otherwise further increase costs, it may materially affect our operations and those of third parties on which we rely, including causing material disruptions in the supply and distribution of our products. The extent to which these conditions impact our results of operations and liquidity will depend on future developments, which are highly uncertain and cannot be predicted, including global supply chain constraints, inflation, tariffs, global conflicts and trade actions/disputes. These effects could have a material adverse impact on our business, liquidity, capital resources and results of operations and those of the third parties on which we rely.

Manufacturing

Certain of our third-party manufacturers have experienced, and may continue to experience, difficulty meeting demand, which has contributed to shortages of certain products, particularly sterile eye care products, as a result of manufacturing improvement initiatives, heightened regulatory scrutiny and evolving regulatory expectations. Recently, all of our sterile eye care manufacturing sites, including those operated by certain third-party manufacturers, have undergone inspections by health authorities, and we and our third-party manufacturers are actively engaging with those authorities and implementing responsive actions intended to strengthen quality systems, improve production consistency and support more reliable supply over time. These activities may result in periods of manufacturing variability, reduced capacity, production delays or product shortages if related remediation, qualification, validation or regulatory readiness activities take longer than expected. These shortages have negatively impacted our results of operations, and further shortages may continue to have a negative impact on sales of our eye care products. We believe these ongoing investments and engagement with health authorities will better position us and our third-party manufacturers to improve supply reliability and support recovery in affected product categories over the long-term.

Income Taxes

Numerous countries have agreed to a statement in support of the Organization for Economic Cooperation and Development ("OECD") model rules that propose a global minimum tax rate of 15%. Certain countries have enacted, or are in the process of enacting, legislation to address the global minimum tax. This legislation has not and is not expected to have a material impact on our Consolidated Financial Statements. As legislation becomes effective in more countries in which we do business, our taxes could increase and negatively impact our provision for income taxes. We continue to monitor pending legislation and implementation by countries and to evaluate the potential impact on our business in future periods.

On July 4, 2025, the One Big Beautiful Bill Act (“OBBBA”) was enacted in the United States. The OBBBA makes permanent key elements of the Tax Cuts and Jobs Act, including 100% bonus depreciation, domestic research cost expensing, and the business interest expense limitation. We evaluated the provisions of the OBBBA and determined that there was no material impact on our estimated annual effective tax rate.

23

Results of Operations

Three Months Ended June 30, 2026 compared to the Three Months Ended June 30, 2025

Total Segment Revenues

In connection with the acquisition of the OTC Wellness Business, the Company established a new product category, Wellness, Sleep & Other, and renamed certain existing product categories. As a result, certain brands were reclassified among product categories. Prior period amounts have been reclassified to conform to the current period presentation.

The following table represents total revenue by segment, including product groups, for the three months ended June 30, 2026 and 2025.

[Excerpt truncated for page length; source filing is linked above.]

Latest 10-K MD&A (excerpt)

Latest 10-K Item 7 source: 0001295947-26-000016. The complete FY 2026 MD&A is published at /company/PBH/mda/fy2026/.

Extracted structurally from real Item 7 body heading to real Item 7A/8 boundary. Confidence: high. Filing date: 2026-05-14. Report date: 2026-03-31.

ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion of our financial condition and results of operations should be read together with the Consolidated Financial Statements and related notes included elsewhere in this Annual Report on Form 10-K. This discussion and analysis may contain forward-looking statements that involve certain risks, assumptions and uncertainties that could cause actual results to differ materially from those implied or described by the forward-looking statements. Future results could differ materially from the discussion that follows for many reasons, including the factors described in Part I, Item 1A. “Risk Factors” in this Annual Report on Form 10-K, as well as those described in future reports filed with the SEC.

General

We are engaged in the development, manufacturing, marketing, sales and distribution of well-recognized, brand name OTC health and personal care products to mass merchandisers, drug/drug wholesale, food, dollar, convenience and club stores and e-commerce channels in North America (the United States and Canada) and in Australia and certain other international markets.  We use the strength of our brands, our established retail distribution network, a low-cost operating model and our experienced management team to create our competitive advantage.

We have grown our product portfolio both organically and through acquisitions. We develop our existing brands by investing in new product lines, brand extensions and strong advertising support. Acquisitions of consumer health and personal care brands have also been an important part of our growth strategy. We have acquired well-recognized brands from consumer products and pharmaceutical companies and private equity firms. While certain of these brands have long histories of brand development and investment, we believe that, at the time we acquired them, many were considered “non-strategic” by their previous owners. As a result, these acquired brands did not benefit from adequate management focus and marketing support during the period prior to their acquisition, which created opportunities for us to reinvigorate these brands and improve their performance post-acquisition. After adding a brand to our portfolio, we seek to increase its sales, market share and distribution in both existing and new channels through our established retail distribution network. We pursue this growth through increased spending on advertising and marketing support, new sales and marketing strategies, improved packaging and formulations and innovative development of brand extensions.

Acquisitions

Acquisition of Pillar5

On December 18, 2025, we completed the acquisition of Pillar5, which was funded through a combination of cash on hand and our existing asset-based revolving credit facility.

Based in Arnprior Ontario, Canada, Pillar5 is a leading sterile ophthalmic manufacturer and one of our current Clear Eyes suppliers.

The pro-forma effect of this acquisition on revenues and earnings was not material.

The details of this acquisition are included in the notes to the Consolidated Financial Statements in Part II, Item 8, Note 2 of this Annual Report on Form 10-K.

Pending Acquisition of Foundation Consumer Brands Product Portfolio

On March 19, 2026, we entered into a definitive agreement to acquire certain assets and assume certain liabilities primarily related to a portfolio of over-the-counter consumer health products, including Breathe Right® and certain other brands from Foundation Consumer Brands, LLC. We anticipate the transaction to close in the first half of fiscal 2027.

Economic Environment

There has been economic uncertainty in the United States and globally due to several factors, including evolving fiscal policy, global supply chain constraints, changes in interest rates, a high inflationary environment, geopolitical events, including conflicts in the Middle East, and evolving U.S. and international trade restrictions and tariffs. We expect economic conditions will continue to be highly volatile and uncertain, put pressure on prices and supply, and could affect demand for our products. We have continued to see changes in the purchasing patterns of our consumers, including a shift in many markets to purchasing our products online, and have and may continue to see changes in retailer purchasing patterns due to these consumer patterns and the volatile economic environment.

34

The volatile environment has impacted the supply of labor and raw materials and exacerbated rising input costs. We have and may continue to experience shortages, delays and backorders for certain ingredients and products, difficulty scheduling shipping for our products, as well as price increases from many of our suppliers for both shipping and product costs. We and our manufacturers are currently having, and have had in the past, difficulty meeting demand, which is and has caused shortages of some of our products, particularly eye care products. These shortages have negatively impacted our results of operations, and we expect further shortages will continue to have a negative impact on our sales. If conditions cause further disruption in the global supply chain, the availability of labor and materials or otherwise further increase costs, it may materially affect our operations and those of third parties on which we rely, including causing material disruptions in the supply and distribution of our products. The extent to which these conditions impact our results of operations and liquidity will depend on future developments, which are highly uncertain and cannot be predicted, including global supply chain constraints, inflation, tariffs, global conflicts and trade actions/disputes. These effects could have a material adverse impact on our business, liquidity, capital resources and results of operations and those of the third parties on which we rely.

Critical Accounting Estimates

Our significant accounting policies are described in the notes to the Consolidated Financial Statements included elsewhere in this Annual Report on Form 10-K.  While all significant accounting policies are important to our Consolidated Financial Statements, certain of these policies may be viewed as being critical.  Such policies are those that are both most important to the portrayal of our financial condition and results of operations and require our most difficult, subjective and complex estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses or the related disclosure of contingent assets and liabilities.  These estimates are based on our historical experience and on various other assumptions that we believe to be reasonable under the circumstances.  Actual results may differ materially from these estimates. The following are our most critical accounting estimates:

Revenue Recognition, Customer Programs and Variable Consideration

Revenue is recognized when control of a promised good is transferred to a customer, in an amount that reflects the consideration that we expect to be entitled to receive in exchange for that good. This occurs either when finished goods are transferred to a common carrier for delivery to the customer or when product is picked up by the customer or the customer’s carrier.

Once a product has transferred to the common carrier or been picked up by the customer, the customer is able to direct the use of, and obtain substantially all of the remaining benefits from, the product. It is at this point that we have a right to payment and the customer has legal title.

Provisions for certain rebates, customer promotional programs, product returns and discounts to customers are accounted for as variable consideration and recorded as a reduction in sales.

We record an estimate of future product returns, chargebacks and logistics deductions concurrent with recording sales, which is made using the most likely amount method that incorporates (i) historical return rates, (ii) current economic trends, (iii) changes in customer demand, (iv) product acceptance, (v) seasonality of our product offerings and (vi) the impact of changes in product formulation, packaging and advertising.

We participate in the promotional programs of our customers to enhance the sale of our products. These promotional programs consist of direct-to-consumer incentives, such as coupons and temporary price reductions, as well as incentives to our customers, such as allowances for new distribution including slotting fees, and cooperative advertising. The costs of such activities are recorded as a reduction to revenue when the related sale takes place. Estimates of the costs of these promotional programs are derived using the most likely amount method, which incorporates (i) historical sales experience, (ii) the current promotional offering, (iii) forecasted data, (iv) current market conditions and (v) communication with customer purchasing/marketing personnel. At the completion of the promotional program, the estimated amounts are adjusted to actual results.

Goodwill and Intangible Assets

At March 31, 2026 and 2025, goodwill and intangible assets were apportioned among similar product groups within our operating segments as follows:

35

March 31, 2026
(In thousands)North American OTC HealthcareInternational OTC HealthcareConsolidated
Goodwill$550,987$30,122$581,109
Intangible assets
Indefinite-lived2,068,75274,9232,143,675
Finite-lived138,90317,027155,930
Intangible assets, net2,207,65591,9502,299,605
Total$2,758,642$122,072$2,880,714
March 31, 2025
(In thousands)North American OTC HealthcareInternational OTC HealthcareConsolidated
Goodwill$498,936$28,489$527,425
Intangible assets
Indefinite-lived2,068,75268,2342,136,986
Finite-lived141,23417,130158,364
Intangible assets, net2,209,98685,3642,295,350
Total$2,708,922$113,853$2,822,775

At March 31, 2026, the brands with the highest carrying value were Monistat, BC/Goody's, Summer's Eve, TheraTears and Fleet, comprising approximately 59% of our total intangible assets value.

Goodwill and intangible assets comprise the majority of all of our assets.  Goodwill represents the excess of the purchase price over the fair value of assets acquired and liabilities assumed in a business combination.  Intangible assets generally represent our tradenames, brand names and patents.  When we acquire a brand, we are required to make judgments regarding the value assigned to the associated intangible assets, as well as their respective useful lives.  Management considers many factors both prior to and after the acquisition of an intangible asset in determining the value, as well as the useful life, assigned to each intangible asset that we acquire or continue to own and promote.

The most significant factors are:

•Brand History

A brand that has been in existence for a long period of time (e.g., 25, 50 or 100 years) generally warrants a higher valuation and longer life (sometimes indefinite) than a brand that has been in existence for a very short period of time.  A brand that has been in existence for an extended period of time generally has been the subject of considerable investment by its previous owner(s) to support product innovation and advertising and marketing.

•Market Position

Consumer products that rank number one or two in their respective market generally have greater name recognition and are known as quali

[Excerpt truncated for page length; the complete text is on the linked full-MD&A page.]

Read the full FY 2026 MD&A or browse all MD&A years.

MD&A history

Prior-year 10-K MD&A spans are extracted from SEC filings with the same bounded parser used for the latest filing. Each year's full verbatim text is on its own sub-page.

FDA-approved drug applications

Applications listed under this company's exact-matched sponsor name. Approved applications only.

No resolved FDA applications were found for this company under the exact-unique, approved-only publish rule.

Sponsor as listed in Drugs@FDA at retrieval (2026-08-07); FDA sponsor listings can lag ownership transfers.

This list covers FDA applications whose listed sponsor name maps to this company by an exact-unique match; applications listed under sponsor names not mapped to this company (subsidiaries, name variants, joint ventures) are absent.

Macro cross-references for PBH

Indicators mapped to this company's SIC classification (industry 2834 Pharmaceutical Preparations) by grepcent's deterministic macro-sector crosswalk. A navigational mapping, not a statistical or causal claim.

Macro-to-micro threads including this sector: Inflation (CPI / PCE / PPI), US labor market, Growth & output, Money & trade, Government finances, Sector employment, Industrial orders & inventories, Trade & external.

All 71 macro indicators →

For LLMs & downloads

Markdown twin: /company/PBH.md · JSON record: /company/PBH.json · verified financials: JSON / CSV · machine TOC for the whole site: /llms.txt